Personalized cancer vaccine succeeds in melanoma trial

Merck and Moderna have presented results from a phase 3 trial of their personalized mRNA vaccine in patients with melanoma. Melanoma is an aggressive form of skin cancer. An earlier, smaller study had already shown a positive signal. The new, larger trial confirms it, a finding that carries clinical weight for regulatory approval.

The vaccine works like this: the DNA of a patient’s tumor is analyzed. From that, so-called neoantigens are identified: protein fragments unique to that specific tumor that the immune system should recognize. The vaccine, built with mRNA technology, instructs the immune system to attack these neoantigens.

Why personalization makes this approach so promising

The researchers emphasize that the unique feature of this approach is its personalization. No two tumors are alike, and traditional vaccines cannot account for that. Because the mRNA platform can be manufactured quickly, a tailored vaccine for each patient can be produced within weeks. That was technically unthinkable a decade ago.

Industry observers have described the results as among the most consequential in cancer treatment in recent decades. By comparison, successful results with a KRAS-targeted therapy for colorectal cancer were also presented this year. Together, the two developments mark 2026 as a potentially historic year for oncology.

What this means for cancer and aging

Cancer is fundamentally a disease of genetic instability that increases with age. As the immune system ages, it loses its ability to recognize and eliminate tumor cells. Therapies that restore that ability, such as this vaccine, are therefore relevant in the context of aging as well. Whether the approach works in other cancer types and in older patients with reduced immune responses is a crucial open question for future research.

Read the original article